A cyclin D1-CDK4/6-E2F dependency represents an acquired vulnerability in cisplatin-resistant bladder cancer. Hsieh TH, Kuo HP, Pan CH, Lin YC, et al. Biol Direct 2026 Apr 27. doi: 10.1186/s13062-026-00812.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hsieh TH, Kuo HP, Pan CH, Lin YC, et al. A cyclin D1-CDK4/6-E2F dependency represents an acquired vulnerability in cisplatin-resistant bladder cancer. Biol Direct 2026 Apr 27. doi: 10.1186/s13062-026-00812.
PMID: 42045965